In collaboration with the South African Health Products Regulatory Authority (SAHPRA) Bristol-Myers Squibb and Key Oncologies (Ply) Ltd would like to draw your attention to the risk of errors in prescribing, dispensing, preparing and administering different parenteral formulations of amphotericin B. ...
In collaboration with the South African Health Products Regulatory Authority (SAHPRA), JANSSEN PHARMACEUTICA (PTY) LTD, would like to inform you of the risk of severe cutaneous adverse reactions in patients treated with Eprex®. ...
The following pharmaceutical companies: AXIM Pharmaceuticals (Pty) Ltd, Guerbet South Africa (Pty) Ltd and GE Healthcare SA in collaboration with South African Health Products Regulatory Authority (SAHPRA) would like to inform you of the safety information regarding the risk of gadolinium brain deposition following the...
ViiV Healthcare would like to inform you of a potential safety issue which has been brought to our attention by the Principal Investigator of the above study conducted in Botswana. The potential safety issue is related to Neural Tube Defect (NTD) cases in infants born...
In collaboration with the South African Health Products Regulatory Authority (SAHPRA), the below listed companies would like to inform you of a risk of acute kidney injury (AKI) in patients treated concomitantly with ACE inhibitors / Angiotensin Receptor Blockers (ARBs) and fluoroquinolones....
In collaboration with the South African Health Products Regulatory Authority (SAHPRA), the below listed companies would like to inform you of a risk of acute kidney injury (AKI) in patients treated concomitantly with ACEIs / Angiotensin Receptor blockers (ARBs) and fluoroquinolones....
In collaboration with the South African Health Products Regulatory Authority (SAHPRA), the below listed companies would like to inform you of a risk of acute kidney injury (AKI) in patients treated concomitantly with Angiotensin Converting Enzyme Inhibitors (ACEIs) Angiotensin receptor blockers (ARBs) and fluoroquinolones....
In collaboration with the South African Health Products Regulatory Authority (SAHPRA), the below listed companies would like to inform you of a risk of acute kidney injury (AKI) in patients treated concomitantly with ACEls / Angiotensin receptor blockers (ARBs) and fluoroquinolones. ...
In collaboration with the South African Health Products Regulatory Authority (SAHPRA), the below listed companies would like to inform you of a risk of acute kidney injury (AKI) in patients treated concomitantly with Angiotensin-converting enzyme inhibitors (ACEls) / Angiotensin receptor blockers (ARBs) and fluoroquinolones.
Notification of an important new warning with treatment of patients with anti phospholipid syndrome (APS) and the use Pradaxa: Increased risk of thrombo-embolic events ...